Skip to main content
← All trials
Cardiovascular DiseaseDrugPhase 3

What this study is

The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp[a]).

What's being tested

  • Olpasiran

    Intervention · DRUG

    Olpasiran will be administered via SC injection.

  • Placebo

    Intervention · DRUG

    Placebo will be administered via SC injection.

Study details

Official title
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)
Sponsor
Amgen
Conditions
Cardiovascular Disease
Enrolling
11,000 people
Starts
2025-08-22
Est. completion
2031-10-20
Design
Double-blind, randomized, parallel groups, Phase 3
Record
View on ClinicalTrials.gov ↗